Much has been written about the recent explosion of biotech IPOs, and last week they accounted for seven of the ten IPOs that priced. Together, they had an average deal size of less than $70 million, and averaged a 16% return. Revance (RVNC), a biotech...read more
Ladder Capital, a commercial real estate mortgage origination and finance company, raised $225 million by offering 13.3 million shares at $17, the midpoint of the $16-$18 range. Ladder Capital plans to list on the NYSE under the symbol LADR. Deutsche Bank, Citi,...read more
Dicerna Pharmaceuticals (DRNA) gained 207% and Ultragenyx (RARE) followed with a 101% first-day jump the next day as the biotech boom reached a new gear last week. Dicerna’s first-day return was the best since Baidu’s IPO in 2005 (+354%), and...read more
US IPO Recap: Revance jumps 68% in ten-IPO week
Much has been written about the recent explosion of biotech IPOs, and last week they accounted for seven of the ten IPOs that priced. Together, they had an average deal size of less than $70 million, and averaged a 16% return. Revance (RVNC), a biotech...read more
Ladder Capital prices IPO at $17 midpoint
Ladder Capital, a commercial real estate mortgage origination and finance company, raised $225 million by offering 13.3 million shares at $17, the midpoint of the $16-$18 range. Ladder Capital plans to list on the NYSE under the symbol LADR. Deutsche Bank, Citi,...read more
US IPO Recap: Ultragenyx doubles and Dicerna triples in home-run week for biotech IPOs
Dicerna Pharmaceuticals (DRNA) gained 207% and Ultragenyx (RARE) followed with a 101% first-day jump the next day as the biotech boom reached a new gear last week. Dicerna’s first-day return was the best since Baidu’s IPO in 2005 (+354%), and...read more
12 US IPOs planned for the week of Feb 3
The following IPOs are expected to price this week: Argos Therapeutics (ARGS), which is developing immunotherapies for the treatment of cancer and HIV, plans to raise...read more